Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.44 |
| ▸ | GABRE | P78334 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.44 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.44 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2982920 | 0.98 | GABRP (0.43) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL856746 | 0.87 | SLC6A4 (0.48) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| SCHEMBL1221396 | 0.87 | SLC6A4 (0.48) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| SCHEMBL1189935 | 0.87 | SLC6A4 (0.48) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| Hydrochloric Acid SCHEMBL4469740 | 0.85 | SLC6A4 (0.47) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| Hydrochloric Acid SCHEMBL4469742 | 0.85 | SLC6A4 (0.47) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| Hydrochloric Acid SCHEMBL2013500 | 0.85 | SLC6A4 (0.47) | GABRA5GABRA1GABRB2GABRA4SLC6A4 | |
| SCHEMBL217412 | 0.83 | — | — | |
| SCHEMBL295900 | 0.82 | GABRA1 (0.39) | GABRA5GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL16424652 | 0.82 | EPHX1 (0.41) | GABRA5GABRA1TSHRGABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3085700-B1 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USAGE THEREOF | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-10-31 | — | — | EP | claimed |
| EP-4384518-A1 | TYROSINE KINASE INHIBITORS | The University Court Of The University of Edinburgh (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4366834-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024035627-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313991-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023083716-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023017264-A1 | TYROSINE KINASE INHIBITORS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
| EP-1314733-A1 | Indole-2-carboxamides as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-0457686-B1 | Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1994-08-03 | — | — | EP | disclosed |
| EP-0457686-A1 | Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-11-21 | — | — | EP | disclosed |
| US-4912219-A | 2-[4-pyrimidin-2-yl amino)piperidin-1-yl]benzimidazole compound | SYNTHELABO (FR) | 1990-03-27 | — | — | US | disclosed |
| US-4820710-A | ANTIALLERGENS, ANTIHISTAMINES, ANTIINFLAMMATORY AGENTS | SYNTHELABO (FR) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | GABRA5 1418/4885GABRA1 1857/4885TSHR 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.